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Abstract
Background Reductions in skeletal muscle mass and in-
creased adiposity are key elements in the aging process and
in the pathophysiology of several chronic diseases. Systemic
low grade inflammation associated with obesity has been
shown to accelerate the age-related decline in skeletal muscle.
The aim of this investigation was to determine the effects of
12 months of progressive resistance training (PRT) on sys-
temic inflammation, and whether reductions in systemic in-
flammation were associated with changes in body composi-
tion. We hypothesized that reductions in systemic inflamma-
tion following 12 months of PRT in older adults with type 2
diabetes would be associated with reductions in adiposity and
increases in skeletal muscle mass.
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Methods Participants (n=103) were randomized to receive
either PRT or sham-exercise, 3 days a week for 12 months.
C-reactive protein (CRP) was used to assess systemic inflam-
mation. Skeletal muscle mass and total fat mass were deter-
mined using bioelectrical impedance.
Results Twelve months of PRT tended to reduce CRP com-
pared to sham exercise (β=−0.25, p=0.087). Using linear
mixed-effects models, the hypothesized relationships between
body composition adaptations and CRP changes were signifi-
cantly stronger for skeletal muscle mass (p=0.04) and tended to
be stronger for total fat mass (p=0.07) following PRT when
compared to sham-exercise. Using univariate regression
models, stratified by group allocation, reductions in CRP were
associated with increases in skeletal muscle mass (p=0.01) and
reductions in total fat mass (p=0.02) in the PRT group, but not
in the sham-exercise group (p=0.87 and p=0.32, respectively).
Conclusions We have shown for the first time that reductions in
systemic inflammation in older adults with type 2 diabetes
following PRTwere associated with increases in skeletal muscle
mass. Furthermore, reductions in CRP were associated with
reductions in adiposity, but only when associated with PRT.
Lifestyle interventions aimed at reducing systemic inflammation
in older adults with type 2 diabetes should therefore incorporate
anabolic exercise such as PRT to optimize the anti-inflammatory
benefits of favorable body composition adaptations.
Keywords PRT . Inflammation .Bodycomposition .Skeletal
muscle . Adiposity
Abbreviations
SMM Skeletal muscle mass
FM Total fat mass
BMI Body mass index
VAT Visceral adipose tissue area
CSA Cross-sectional area
CRP C-reactive protein
PRT Progressive resistance training
SHAM Sham-exercise training group
BIA Bioelectrical impedance assessment
CT Computed tomography
RCT Randomized controlled trial
HbA1c Glycated hemoglobin
1 Introduction
Type 2 diabetes mellitus is a chronic condition characterized
by the presence of insulin resistance, systemic low-grade
inflammation, and an increased risk of cardiovascular disease.
Increasing evidence suggests that the presence of inflamma-
tion is a key factor in the development and progression of
insulin resistance, as well as other cardiovascular disease co-
morbidities such as atherosclerosis [1, 2]. C-reactive protein
(CRP) is a biomarker commonly used as an index of systemic
inflammation and has been shown to be an independent pre-
dictor of cardiovascular disease mortality [3, 4].
Excess adiposity, particularly visceral adipose tissue (VAT),
is central to increased levels of circulating CRP [5, 6], while
CRP is known to accelerate age-related loss of skeletal muscle
mass (SMM) [7], highlighting CRP’s dual association with
body composition. PRT is a unique mode of exercise that can
reduce adiposity whilst concomitantly increasing SMM, thus
potentially addressing the two body composition parameters
associated with increased CRP. The aim of this investigation
was therefore to determine the effect of 12 months of high
intensity PRT on circulating CRP in older adults with type 2
diabetes, and whether improvements in body composition (in-
creases in SMM and reductions in adiposity) were related to
reductions in CRP. Our hypotheses were as follows:
1. CRP would be significantly associated with indices of
adiposity and SMM at baseline.
2. PRT would significantly reduce CRP compared to the
sham-exercise control group.
3. Reductions in CRP would be associated with favorable
changes in body composition variables, namely increased
SMM and mid-thigh muscle area, and decreased FM and
VAT.
2 Materials and Methods
The GREAT2DO study is an ongoing clinical trial investigat-
ing the efficacy of 6 years of PRT on insulin resistance and
glucose homeostasis in older adults with type 2 diabetes. The
first year was a randomized, double-blind, sham-exercise
controlled trial. After the initial year, participants were asked
to continue training, with participants in the sham-exercise
control group crossed over to high intensity PRT. The data
presented in this report are from the RCT phase. Between July
2006 and November 2009, 103 participants were randomized
to receive 12 months of high intensity, high velocity, PRT, or
sham-exercise (low intensity, non-progressive exercise), in
addition to usual care. Inclusion criteria were ≥60 years, sed-
entary (no progressive resistance training; structured exercise
≤1/week; less than 150 min/week low or moderate intensity
walking or other unstructured exercise) and type 2 diabetes
and metabolic syndrome. Participants could be treated with
diet alone, oral medications, insulin, or combination at the
time of enrolment, without recent changes in medication
(<3 months). Randomization was performed using a investi-
gator not involved in the study and was stratified by sex and
insulin usage in blocks of 4. Exclusion criteria for the study
were the presence of unstable chronic diseases or any
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contraindications to PRT, or being unwilling to commit to a
12-month exercise training program, 3 times per week. Writ-
ten informed consent was obtained from all participants, and
the protocol was approved by the Sydney South West Area
Health Service and the University of Sydney Human Research
Ethics Committees (Australian New Zealand Clinical Trial
Registry number 12606000436572).
2.1 Training Protocol
The PRT group trained 3 days per week under supervision
using pneumatic resistance equipment (Keiser Sports Health
Ltd., Fresno, CA), at two sites. A version of PRT known as
power training was employed, in which the concentric con-
traction (lifting) was completed as quickly as possible, whilst
the eccentric contraction (lowering) was completed over 4 s.
The exercises targeted large symmetrical muscle groups of the
arms, legs, and trunk: seated row, chest press, leg press, knee
extension, hip flexion, hip extension, and hip abduction. For
each exercise, participants performed 3 sets of 8 repetitions (2
sets of 8 on each leg for hip flexion, hip extension, and hip
abduction). The intensity was set at 80 % of the most recently
determined 1 repetition maximum (1RM), which was re-
assessed every 4 weeks. When 1RM testing was not feasible,
resistances were increased by targeting a Borg scale rating of
perceived exertion between 15 and 18.
The sham-exercise group trained on the same equipment, 3
times a week, under supervision from the same trainers at
different times of the day so as to remain blinded to the
investigators’ hypotheses, with both interventions offered as
potentially beneficial. The resistance was set as low as possi-
ble and not progressed, and participants were instructed to
perform concentric and eccentric contractions slowly.
2.2 Assessments
Blinded outcome assessments were conducted at 0 and
12 months at the University of Sydney. Participants were
required to withhold food, liquids, and medication for
12 h prior to metabolic testing. A 24-h food recall was
performed on the day of the baseline assessment, and
participants were asked to follow the same diet prior to
subsequent assessments at 12 months. Assessments at
12 months were performed 72 h after each participant’s
final training session.
2.3 Demographics and health status
Participants were asked routine questions to obtain demo-
graphic information, as well as their current health status
relating to prescribed medications, smoking status (current
or past), and the presence of other chronic diseases.
2.4 Measure of systemic inflammation
High-sensitivity CRP was measured in duplicate by enzyme-
linked immunosorbent assay (ELISA; eBIOSCIENCE, Cam-
arillo, CA), with the average value used in statistical analyses.
The lowest detectable concentration was 0.01 mg/L, and the
intra-assay coefficient of variation was 6.3 %. To remove the
potential confounding of acute inflammation, participants
with concentrations of CRP >10 mg/L were excluded from
analyses [4].
2.5 Anthropometric measurements
Morning fasting stretch stature (wall-mounted Holtain
stadiometer, Holtain Limited, Crymych Pembs., UK) and
naked weight [weight in gown (kg)−weight of gown (kg)]
were measured in triplicate to the nearest 0.1 cm and 0.01 kg,
respectively.
2.6 Measures of body composition
SMM and total fat mass (FM) were determined using bioelec-
trical impedance analysis (BIA; RJL Systems, Inc., Clinton,
MI, USA) [8, 9]. All participants were fasting and in a state of
euhydration, and BIA was performed in the morning, at a
similar time of day for all participants. BIAwas not available
in 3 subjects due to presence of a pacemaker. SMM was
determined using the equation from Janssen et al [8]. Skeletal
musclemass was determined using the following equation [8]:
Skeletal muscle mass ¼ 0:401 height2=BIAþ 3:825 sexð Þ þ 0:071 x ageð Þ þ 5:102
with height in cm, BIA resistance in ohms (average of 3 mea-
sures), sex coded 1 for men and 0 for women, and age in years.
FM was determined using BIA, by subtracting lean
body mass from total mass to determine FM. Lean body
mass was determined using the equation from Lukaski
et al [9].
Lean Body Mass ¼ −4:03þ 0:734 Ht2=BIA 
þ 0:116 BWð Þ þ 0:096 Xcð Þ þ 0:878 sexð Þ
with height (Ht) in cm, BIA resistance in ohms (average of 3
measures), naked body weight (BW) in kg, Xc reactance in
ohms, and sex coded 1 for men and 0 for women
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Computed tomography (CT; GE High Speed CTI Scanner,
MIL, USA at the Royal Prince Alfred Hospital, Sydney) was
used to quantify VAT (cm2), mid-thigh muscle cross-sectional
area (cm2; CSA), and mid-thigh muscle attenuation.
For CTscans of the abdomen, a 1-mm-thick slice was taken
at the mid-point between the iliac crest and lowest rib (deter-
mined with the participant supine). This scan location is
concordant with the waist circumference measurement site
used by the International Diabetes Federation and is a criterion
used by the IDF to classify metabolic syndrome [10]. Settings
were kV=100 and mA=170 with a displayed field of view
(DFOV) 45–48, depending on subject size.
For CTscans of the mid-thigh, a 1-mm slice was performed
at the mid-point between the inguinal crease and the proximal
pole of the patella measured with the subject supine and knee
flexed. The non-dominant leg was used. Settings were kV=
100 and mA=170 with a (DFOV) 25. Scan images were
analysed according to optical density by a blinded investigator
using NIH Image software (Version 1.63, National Institutes
of Health) programmed with specific macros to quantify
cross-sectional adipose tissue. To determine VAT, macros
were programmed to select the outer perimeter extending from
the paraspinal muscles to the anterior abdominal muscles. The
program calculated this measure by summing the area within
the selected perimeter occupied by pixels with optical density
in the range of 140 to 240. Thigh muscle density was calcu-
lated according to a specific optical density range (10–113)
chosen to best discriminate muscle from fat and bone. Co-
efficient of repeatability (CR), determined using a Bland–
Altman plot on a subset of 10 scans, was found to be excellent
at 0.49 for VAT, 0.44 and for mid-thigh CSA [11].
2.7 Statistical analyses
All data were assessed for normality using histograms and
descriptive statistics. Normally distributed data are presented
as mean±SD; otherwise, data are presented as median (range)
or frequencies as appropriate. CRP data required square root
transformation to achieve normal distribution for use with
parametric statistics. Comparisons of variables between
groups were performed using a one-way ANOVA. Linear
regressions were performed to determine the relationship be-
tween continuous variables at baseline. A linear mixed-effects
model with repeated measures was used to determine changes
over time as this method allows for all available data to be
used without imputation for missing values. CRP was entered
as the dependent variable with group, time, and group × time
interaction entered as fixed effects and an unstructured covari-
ance matrix. To determine if there was any association be-
tween group assignment and changes in measures of body
composition on reductions in CRP, sequential linear mixed
models were constructed with CRP as the dependent variable
and full factorial interaction between group, time and the
change in the body composition variable of interest. Any
variables found to be associated with CRP using mixed-
effects models (p<0.10) were then explored using linear re-
gression models stratified by group allocation. A p value
<0.05 indicated statistical significance as all hypotheses were
specified a priori. IBM SPSS version 21 (SPSS Inc. Chicago,
IL, USA) was used for all analyses.
3 Results
Participant flow relevant to this report is shown in Fig. 1.
Participant characteristics are presented in Table 1. Three
participants withdrew prior to commencing the intervention
and were thus excluded from the analyses. Among the re-
maining 100 participants, CRP data were available in 91 at
either baseline or 12-month time points. However, 4 partici-
pants had a baseline CRP>10 mg/L, 2 of whom had a follow-
up CRP>10 mg/L, while the other 2 subsequently dropped
out and thus provided no follow-up sample, resulting in all
CRP data from these 4 participants to be removed from
analysis as recommended here [4]. Thus, baseline data from
the remaining 88 participants are shown in Table 1. At base-
line, no difference was observed in CRP between participants
in the PRT group and the sham-exercise group (p=0.69).
Participants in the sham-exercise group had a significantly
higher HbA1c (p=0.03) and tended to have a longer duration
of diabetes (p=0.09) at baseline, but did not differ in any other
demographic, body composition, or metabolic health param-
eters (p=0.10-0.96). Median compliance to the intervention
was 82 % (range; 87 %), with the median attendance rate of
77 % (range; 86 %) in the PRT group non-significantly lower
than themedian attendance of 83% (range; 84%) in the sham-
exercise group (p=0.28).
3.1 Associations between body composition and CRP
at baseline
Results are presented in Table 2. As hypothesized, CRP was
directly associated with body weight (r=0.53, p<0.0001) and
BMI (r=0.52, p<0.0001) and FM (r=0.59, p<0.0001); but
unexpectedly, only a trend was observed with VAT (r=0.21,
p=0.10). SMM was directly associated with CRP (r=0.33,
p<0.01); however, mid-thigh CSA was not associated with
CRP (r=0.03, p=0.84).
A stepwise multiple regressionmodel was then constructed
with CRP entered as the dependent variable, and SMM and
BMI entered as the independent variables, since both variables
were related to CRP, and did not display colinearity (r=0.51).
In this model, only BMI was associated with CRP (r=0.50,
p<0.0001), while SMM no longer showed any independent
association (r=0.08, p=0.53). Body weight was unable to be
used as this displayed colinearity with SMM (r>0.7).
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Similarly, FM displayed colinearity with body weight and
BMI (r>0.7), and thus precluded the use of this variable in
the model.
3.2 Changes in body composition
Data for the full cohort of participants has been previously
reported here [12]. In line with our previously reported data,
there was also no group × time interaction for changes in
whole body SMM or FM within this subset with CRP data
(data not shown). However, in contrast to the whole cohort, a
significant group × time interaction was found within this
subset for changes in mid-thigh CSA (β=5.49, p=0.03) and
VAT (β=−19.14, p=0.03) in favor of the PRT group.
3.3 Changes in CRP
Results are presented in Table 2. Using a linear mixed-effects
model, a trend for a group × time interaction was present, with
greater reductions in CRP in the PRT group relative to sham-
exercise, as hypothesized (β=−0.25, p=0.087).
3.4 Association between changes in body composition
and changes in CRP
Results are presented in Table 3. Changes in body composi-
tion variables were entered as covariates, with a full factorial
interaction with group and time to compare the effects of
changes in body composition on CRP between the PRT and
sham groups. In these models, increases in SMM in the PRT
group were significantly associated with reductions in CRP
compared to increases in SMM in the sham group (β=−0.23,
p=0.04). Similarly, reductions in FM tended to be significant-
ly associated with reductions in CRP in the PRT group com-
pared to reductions in FM in the sham group (β=0.09,
p=0.07). No differences between the PRTand sham groups in
terms of the relationship with CRP were observed with chang-
es in body weight (β>−0.01, p=0.94), BMI (f<0.01, β=0.01,
Sham-exercise Group
Allocated to intervention (n=54)
Withdrew prior to commencing intervention (n=1)
Received allocated intervention (n=53)
Assessed for eligibility (n=427)
Excluded (n=324)
Not meeting inclusion criteria (n=285)
Declined to participate (n=15)
Other reasons (n=24)
All available data using linear fixed-effects model
(n=41)a
CRP data available at baseline (n=39)
CRP data available at 12 months (n=30)
Did not complete final assessment (n=10)
Medical (n=2), Commitment issue (n=1), Too hard
(n=5), Disinterest (n=1), Adverse event (n=1)
Discontinued intervention (n=4)
PRT Group
Allocated to intervention (n=49)
Withdrew prior to commencing intervention (n=2)
Received allocated intervention (n=47)
Did not complete final assessment (n=4) 
Medical, (n=2), Commitment issue (n=2)     
Discontinued intervention (n=1)
All available data using linear fixed-effects model
(n=47)b
CRP data available at baseline (n=41)
CRP data available at 12 months (n=39)
Allocation
Analysis
Follow-Up
Randomized (n=103)
EnrolmentFig. 1 CONSORT participant
flow chart. PRT progressive
resistance training. a Forty-one
participants were derived from 11
participants with baseline data
only, 2 participants with 12-
month data only, and 28
participants with both baseline
and 12-month data. b Forty-one
participants were derived from 8
participants with baseline data
only, 5 participants with 12-
month data only, and 34
participants with both baseline
and 12-month data
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p=0.95), VAT (β<0.01, p=0.56), mid-thigh CSA (β=0.01,
p=0.70), or mid-thighmuscle attenuation (β=−0.03, p=0.73).
Due to the significant interaction noted above of group,
time, and body composition change, we stratified by group
Table 1 Baseline participant characteristics
Variable Total, n=88 PRT, n=41 SHAM, n=47 p value
Demographics
Age (years) 68.2±5.7 67.2±4.9 69.2±6.3 0.10
Sex (men/women) 46/42 22/19 24/23 0.81
Duration of diabetes (years) 7 (28) 6 (27) 8 (28) 0.06
Number of chronic diseases (n) 5.1±1.9 5.1±1.9 5.0±1.8 0.80
History of smoking (yes/no)a 51/31 24/14 27/17 0.87
Current smoker (yes/no) 6/81 3/39 3/42 0.86
Number of medications (n) 5.7±3.0 5.2±2.8 6.1±3.1 0.15
Number on insulin (yes/no) 15/73 7/34 8/39 0.78
Metformin users (yes/no) 64/24 30/11 34/13 0.93
Metformin dosage (mg/day) 1541±666 1548±646 1534±693 0.93
Metabolic health
CRP 2.1 (9.9) 2.4 (9.9) 2.1 (9.4) 0.69
HOMA2-IRb 2.7±1.1 2.7±1.0 2.8±1.2 0.55
HbA1c (%) 7.1±1.1 6.8±0.8 7.4±1.3 0.03
HbA1c (mmol/mol) 54±12 51±9 57±14 0.03
Body composition
Body weight (kg) 89.0±16.3 89.8±16.0 88.3±16.7 0.66
BMI (kg/m2) 31.3±5.1 31.1±4.8 31.4±5.4 0.80
Skeletal muscle mass (kg) 30.6±4.0 31.0±4.5 30.3±3.6 0.43
Total fat mass (kg) 31.1±10.8 31.4±10.4 30.9±11.3 0.81
VAT (cm2) 214.6±90.0 221.0±88.3 209.0±92.0 0.54
Mid-thigh CSA (cm2) 110.5±24.0 111.6±26.4 109.6±21.9 0.70
Mid-thigh muscle attenuation 84.3±2.3 84.3±2.3 84.2±2.4 0.79
Normally distributed data presented as mean±SD. Non-normally distributed data presented as median (range). Difference between groups was assessed
via one-way ANOVA. Duration of diabetes data were log-transformed before use with parametric statistics. CRP data required square-root transforma-
tion before use with parametric statistics. Categorical variables were assessed using a chi-square. Mid-thigh muscle attenuation is a measure of
intramuscular lipid accumulation. Higher mid-thigh muscle attenuation index (unitless measure based on optical density gradient from image analysis of
CT scans) indicates greater intramuscular lipid
PRT progressive resistance training group, SHAM sham-exercise training group,CRPC-reactive protein,HOMA2-IRHomeostatic Model of Assessment
of Insulin Resistance 2, HbA1c glycated hemoglobin, BMI body mass index, CSA cross-sectional area, VAT visceral adipose tissue area
a This excludes current smokers
b 15 participants (7 PRT and 8 SHAM) were excluded from HOMA2-IR analyses due to insulin therapy
Table 2 Changes in CRP
PRT group SHAM group f β p GxT
Pre Post Pre Post
n Mean±SD n Mean±SD n Mean±SD n Mean±SD
CRP (mg/L) 39 2.37 (9.88) 30 1.60 (6.90) 41 2.07 (9.43) 39 1.84 (9.77) 3.03 −0.25 0.087
Data presented as median (range) of raw values. Difference between groups was assessed via linear mixed-effects modeling with an unstructured
covariance matrix. Data required square-root transformation before use with parametric statistics
GxT group × time interaction, CRP C-reactive protein, PRT progressive resistance training, SHAM sham exercise control
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assignment to explore the relationships within each group.
Using univariate regression models, stratified by group allo-
cation, a significant inverse association was found between
changes in CRP and changes in SMM in the PRT group (r=
−0.48, p=0.01), but this was not seen in the sham-exercise
group (r=0.03, p=0.87; Fig. 2a). Similarly, changes in CRP
were directly related to changes in FM within the PRT group
(r=0.45, p=0.02), but not in the sham group (r=−0.18, p=
0.32; Fig. 2b).
4 Discussion
We have shown that 12 months of PRT tended to reduce CRP
compared to sham-exercise in older adults with type 2
diabetes. There is conflicting evidence from previous litera-
ture regarding the ability of PRT to reduce systemic inflam-
mation [13], including recent trials in individuals with type 2
diabetes [14, 15]. However, for the first time, we have shown
that reductions in CRP were mediated, in part, by increases in
skeletal muscle following high intensity PRT. Similarly, re-
ductions in FM tended to mediate the reduction in CRP in the
PRT group. These results were further confirmed by our linear
regression models stratified by group allocation (Fig. 2a, b),
with significant associations only seen in the PRT group and
not the sham group. Previously, we showed similar associa-
tions between increases in SMM and reductions in FM with
insulin resistance and glucose homeostasis within the same
cohort [12], and so the present study provides further evidence
that PRT should be incorporated into treatment strategies for
Table 3 Changes in body composition variables and changes in CRP
PRT group SHAM group SHAM-PRT group
β p β p β p
Body weight (kg) 0.01 0.82 0.01 0.70 0.00 0.94
BMI (kg/m2) 0.03 0.72 0.03 0.75 0.01 0.95
Skeletal muscle mass (kg) −0.16 0.06 0.07 0.34 −0.23 0.04
Total fat mass (kg) 0.06 0.12 −0.03 0.31 0.09 0.07
VAT (cm2) 0.00 0.71 0.00 0.64 0.00 0.56
Mid-thigh CSA (cm2) 0.00 0.90 −0.01 0.63 0.01 0.70
Mid-thigh muscle attenuation 0.06 0.36 0.09 0.09 −0.03 0.73
Mid-thigh muscle attenuation is a measure of intramuscular lipid accumulation. Higher mid-thigh muscle attenuation index (unitless measure based on
optical density gradient from image analysis of CT scans) indicates greater intramuscular lipid
CRP C-reactive protein, BMI body mass index, CSA cross-sectional area, VAT visceral adipose tissue area
Fig. 2 Changes in body composition vs. changes in CRP.CRPC-reactive
protein. a Reductions in CRP were related to increases in skeletal muscle
mass in the PRT group (closed circles, solid line; r=−0.48, p=0.01) but not
in the sham-exercise group (open squares, dashed line; r=0.03, p=0.87).
Linear mixed-effects models showed that the relationship within the PRT
groupwas significantly different to the relationship in sham-exercise group
(β=−0.23, p=0.04). b Reductions in CRP were directly related to reduc-
tions in total fat mass in the PRT group (closed circles, solid line; r=0.45,
p=0.02) but not in the SHAM group (open squares, dashed line; r=−0.18,
p=0.32). Our linear mixed-effects models showed that the relationship
within the PRT group tended to be significantly different to the relationship
in sham-exercise group (β=0.09, p=0.07)
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individuals with type 2 diabetes in order to improve their body
composition, systemic inflammation, and their metabolic
health.
The data in this study highlight the association between
body composition and systemic inflammation in older adults
with type 2 diabetes, and suggest that both increases in SMM
and reductions in adiposity be targeted with lifestyle interven-
tions within this cohort. This concept is further supported by
findings that changes in CRP were not associated with chang-
es in either body weight or BMI. This is in agreement with
Balducci et al [15] who reported that 12 months of either
aerobic training, or a combination of aerobic and PRT resulted
in reductions in CRP independent of weight loss within indi-
viduals with type 2 diabetes. Concomitant increases in SMM
and reductions in adiposity may result in minimal changes in
body weight; however, given their dual positive effects on
reducing CRP, reductions in systemic inflammation may be
observed that are not associated with overall weight loss. This
is also true for other metabolic outcomes within individuals
with type 2 diabetes [16].
4.1 Association between skeletal muscle and CRP
The direct association between SMM and CRP at baseline
within our cohort is in agreement with previous investigations
reporting the cross-sectional relationship between systemic
inflammation and SMM or lean body mass in other cohorts
[17, 18]. The authors in prior studies concluded that lean tissue
might in fact contribute to systemic inflammation. However,
our analyses show that after adjusting for BMI, SMM is no
longer associated with CRP. This is likely due to the direct
relationship between SMM and BMI; with over nutrition and
excess adiposity resulting in a higher quantity of SMM. Fur-
thermore, our longitudinal data, in agreement with some but
not all previous investigations [13] indicate that anabolic
exercise such as PRT can reduce systemic inflammation.
Furthermore, our linear mixed-effects models and linear re-
gression models indicate that increases in SMM following
PRT were associated with reductions in CRP, indicating that
increasing lean tissue with anabolic exercise may potentially
mediate reductions in systemic inflammation.
Given that CRP has been shown to predict the loss of SMM
in older adults [7], the observed association between reduc-
tions in CRP with increases in SMM is of great significance.
Previous data within a similar cohort showed no relationship
between changes in lean body mass and changes in CRP
following 4 months of PRT [19]. To our knowledge, ours is
the only other study to investigate the relationship between
changes in markers of systemic inflammation, and changes in
lean tissue in a cohort of individuals with type 2 diabetes.
Therefore, our results provide a significant and novel advance
in knowledge in this field. A notable difference between our
study and that of Brooks et al [19] is that in the latter, this
relationship was explored between changes in CRP and
changes in quadriceps muscle type I fiber cross-sectional area
only, as opposed to whole body SMM within our investiga-
tion. It is possible that changes in whole body SMM are more
reflective of changes in systemic inflammation. In agreement
with this, increases in regional indices of SMM (CT scan)
within our cohort showed no relationship with reductions in
CRP. Further studies utilizing more precise whole body com-
position techniques such as dual-energy X-ray absorptiometry
or multi-slice MRI scanning are required to further explore
this relationship.
4.2 Association between adiposity and CRP
Figure 2b illustrates that reductions in CRP following PRT
were related to reductions in fat mass. This is important, given
the predictive value of CRP in CVD. Until recently, CRP was
believed to be produced exclusively by hepatocytes, namely
in response to circulating interleukin-6 (IL-6) [20]. However,
production of CRP within subcutaneous and visceral adipose
tissue has also been reported [21–23]. Thus, reductions in
circulating CRP can be influenced both directly, and indirect-
ly, by reductions in adipose tissue. The finding that CRP is
produced by both subcutaneous and visceral adipose tissue
supports our finding that reductions in FM (inclusive of both
depots) predicted reductions in CRP, rather than VAT in iso-
lation. In addition to adipose tissue, macrophages and smooth
muscle cells from atherosclerotic plaques [24–26] and in-
flamed renal epithelial cells [27] have been shown to contrib-
ute to circulating levels of CRP. Adipose tissue is a major
contributor to circulating cytokines, which could initiate or
mediate local inflammatory responses (including CRP pro-
duction) within these tissues [28]. Thus, reduced adiposity
after PRT could have both directly and indirectly reduced
circulating CRP.
4.3 The role of inflammation in adaptations to PRT
Given the known catabolic effects of systemic inflammation,
and its role in anabolic resistance [29], our data suggest that
reductions in CRP may allow more robust increases in SMM
in response to PRT. However, our study does not prove that
reductions in inflammation secondary to reduced adiposity
preceded the skeletal muscle hypertrophy, and thus further
investigations are needed to delineate the time course of these
adaptations to PRT. An alternative pathway to CRP reduction
after PRT is also possible. Skeletal muscle is known to secrete
IL-6 in response to muscle contraction, which can bring about
an anti-inflammatory environment by inducing the production
of the anti-inflammatory cytokines IL-1ra and IL-10 [30].
Importantly, the magnitude of IL-6 production is dependent
on the amount of skeletal muscle recruited [30, 31], which
would be optimized by training with high speeds/volumes/
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intensities/numbers of muscle groups (such as our power
training group). These circulating anti-inflammatory
myokines may also potentially mediate the effects of PRT
by suppressing CRP production within adipose and non-
adipose tissues, thus contributing to reduced inflammation.
These pathways to lower CRP (reduced fat mass and in-
creased muscle contractile activity) may operate simulta-
neously and require further study to determine their relevance
and importance in type 2 diabetes and other cohorts charac-
terized by chronic systemic inflammation.
4.4 Anti-inflammatory efficacy of body composition changes
may depend on how they are achieved
Reductions in FM following PRTwere significantly associated
with reductions in CRP, while reductions in FM following
sham-exercise were not (Fig. 2b), despite similar reductions
in FM between groups, as previously reported [12]. This sug-
gests that not only is reduction in adipose tissue necessary for
reduction in systemic inflammation, but the intervention chosen
to mediate this body composition shift may play an important
role. Other strategies to reduce adipose tissue, such as dietary
changes, would not incorporate any potential therapeutic effect
of skeletal muscle contraction. In addition, dietary restriction by
itself may cause losses of muscle tissue [32] as well as adipose
tissue. Thus, the benefits of fat loss could be attenuated or
eliminated by the adverse effects of muscle loss and reduced
contractile activity on overall inflammatory milieu.
It is also possible that combined strategies to reduce in-
flammation may be even more beneficial than any single
intervention such as anabolic exercise. While our data suggest
that reductions in CRP can be achieved through PRT-mediated
reductions in adiposity, other interventions to reduce systemic
inflammation, such as non-steroidal anti-inflammatory drugs
[33], poly-unsaturated fatty acids [34, 35], or antioxidants
could potentially enhance the anabolic response to PRT in
older adults with type 2 diabetes.
4.5 Future directions, limitations, and conclusions
Most importantly, further prospective studies are needed to
determine the nature of the relationship between CRP and
SMM, which is potentially bi-directional. Elevated CRP
may attenuate a robust response to anabolic stimuli, thus both
leading to sarcopenia and impeding recovery from it. Alter-
natively, sarcopenia/dynapenia and the reduced contractile
activity accompanying this condition could reduce anti-
inflammatory myokine release into the circulation and thus
contribute to an overall enhancement of systemic inflamma-
tory profile. Understanding of these relationships may im-
prove targeting of individuals likely to require augmentation
of standard PRT regimens to enhance body composition and
metabolic outcomes in clinical cohorts.
In conclusion, we have demonstrated that 12 months of
PRT reduced systemic inflammation in older adults with type
2 diabetes, mediated through improvements in body compo-
sition, relationships which were not seen with sham exercise.
The significant associations between changes in CRP and
changes in FM and SMM after PRT indicate that both body
composition compartments should be targeted in evidence-
based lifestyle interventions aimed at maximally reducing
systemic inflammation in older adults with type 2 diabetes.
It is time that the insufficient goal of “weight loss” be replaced
with “muscle gain and fat loss” in overweight/obese cohorts if
optimal metabolic health is to be achieved.
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